NRC Health (NRC) company profile
Close on Nov 17, 2026Market cap $572.57MP/E –Yield 2.01%
About NRC Health
Services-Commercial Physical & Biological Research, SIC 8731
National Research Corporation, doing business as NRC Health, provides experience management solutions, data analytics, and actionable insights for the healthcare sector. The company's digital offerings span four primary categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. In addition, its Governance Solutions, operating as The Governance Institute, deliver advisory services, research, conferences, and publications. These solutions assist healthcare organizations in capturing constituent feedback, evaluating brand perception, engaging clinical staff, and strengthening executive governance. Customers include healthcare systems, hospital boards, executives, and physician leadership across the care continuum.
The company maintains a diversified customer base distributed across the United States. Its syndicated survey database annually measures the opinions and behaviors of approximately 300,000 healthcare consumers across the contiguous United States. National Research Corporation is incorporated in Delaware and operates its principal executive offices in Lincoln, Nebraska.
Summary of the business section of NRC Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NRC Health
- Founded
- 1981
- Headquarters
- Lincoln, NE
- Address
- 1245 Q Street 68508
- Phone
- (402) 475-2525
- Website
- nrchealth.com
- Employees
- 357, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Omaha, Nebraska
Stock & identifiers
- Ticker
- NRC
- Former tickers
- NRCI until May 4, 2018
- Exchange
- Nasdaq
- IPO date
- May 23, 2013
- Shares outstanding
- 22M, Jul 31, 2026
- Public float
- $194.76M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 70487
- CUSIP
- 637372202
- ISIN
- US6373722023
- FIGI
- BBG004K1F8W7
- Share class FIGI
- BBG004K1F9R1
- LEI
- 549300FQIORB6GZCYT15
- EIN
- 47-0634000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael D. Hays | Chairman, Director | 96,249 |
| Trent S. Green | Chief Executive Officer, Director | 500,000 |
| Helen Hrdy | EVP & Chief Operating Officer | 142,646 |
| Jason Russell Rau | Executive Vice President | 60,000 |
| Shane R. Harrison | EVP & Chief Financial Officer | 158,729 |
| David Burik | EVP, Strategic Insights | 100,000 |
| Jordan Nicole Freeman | Chief Accounting Officer | 771 |
| Andrew Monnich | Chief Corp. Development Off. | 100,000 |
| Linda Stacy | Interim Principal Fin. Off. | – |
| Parul Bhandari | Director | 7,697 |
| John N. Nunnelly | Director | 40,363 |
| Penny Ann Wheeler | Director | 7,697 |
| Stephen H. Lockhart | Director | 7,697 |
| Donald M. Berwick | Director | 7,697 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Green | $11.96M | $14.79M | $1.62M | $47 | $134 |
| FY2025 Mr Hays | $184.42K | $203.34K | $1.62M | $47 | $134 |
| FY2024 Mr Green | $0 | $0 | $1.12M | $29 | $143 |
| FY2024 Mr Hays | $184.86K | -$43.48K | $1.12M | $29 | $143 |
| FY2023 Mr Green | $0 | $0 | $428.16K | $64 | $128 |
| FY2023 Mr Hays | $195.57K | $202.17K | $428.16K | $64 | $128 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Trent Green Chief Executive Officer (2) | $697.12K | $4.50M | $6.76M | – | – | $6.45K | $11.96M | – |
| Shane Harrison Chief Financial Officer (2) | $92.31K | $100.00K | $2.29M | – | – | $1.19K | $2.48M | – |
| Helen L. Hrdy EVP & Chief Operating Officer | $400.00K | $826.67K | $1.24M | – | – | $8.18K | $2.47M | +60% |
| Andy Monnich EVP & Chief Corporate Development Officer | $400.00K | $826.67K | $1.24M | – | – | $8.15K | $2.47M | – |
| Jason Rau Executive Vice President, Sales | $362.31K | – | – | – | $249.52K | $7.31K | $619.13K | – |
| Michael D. Hays Chair; Former Chief Executive Officer, President (2) | $127.40K | – | – | $54.55K | – | $2.46K | $184.42K | -0% |
| Linda Stacy Former Interim Principal Financial Officer (2) | $12.50K | – | – | – | – | $47.50K | $60.00K | -76% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed a total of 357 associates.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 27, 2026 | Name change | Name changed from NATIONAL RESEARCH CORP to NRC Health |
| Apr 20, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 17, 2018 | Delisting | Notice of delisting from exchange (Form 25) |
| Apr 17, 2018 | Deregistration | Termination of SEC registration (Form 15) |
| May 16, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 9, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 29, 2008 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 31, 2006 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
See a number that looks wrong?